Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Open Access
- 1 March 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (5), 716-721
- https://doi.org/10.1086/500200
Abstract
Opiate dependence among human immunodeficiency virus (HIV)—infected patients has been associated with negative clinical outcomes, yet few affected paKeywords
This publication has 19 references indexed in Scilit:
- Buprenorphine in the treatment of opioid dependenceEuropean Neuropsychopharmacology, 2004
- Cost and cost‐effectiveness of standard methadone maintenance treatment compared to enriched 180‐day methadone detoxificationAddiction, 2004
- Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and NaloxoneNew England Journal of Medicine, 2003
- Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependenceDrug and Alcohol Dependence, 2003
- From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United StatesDrug and Alcohol Dependence, 2003
- Office-Based Treatment of Opioid-Dependent PatientsNew England Journal of Medicine, 2002
- Office-Based Treatment for Opioid Dependence: Reaching New Patient PopulationsAmerican Journal of Psychiatry, 2001
- HIV transmission and the cost-effectiveness of methadone maintenanceAmerican Journal of Public Health, 2000
- Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAARTDrug and Alcohol Dependence, 2000
- Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatmentAIDS, 2000